# A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

> **NCT00661778** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 50 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00661778
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661778, "A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00661778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*